MEDTIDE (03880) surged over 9% in morning trading, reaching a high of HK$40.54 and setting a new record since its listing. As of press time, the stock was up 8.9% to HK$40.14, with turnover of HK$21.0322 million.

On the news front, MEDTIDE will convene a board meeting on August 29 to approve its interim results. According to Frost & Sullivan data, MEDTIDE ranked as the world's third-largest peptide-focused CRDMO by revenue in 2023, capturing a 1.5% market share. The company provides comprehensive services spanning the entire lifecycle from early discovery, preclinical research, and clinical development to commercial manufacturing.

The top two players in the global peptide-focused CRDMO market hold a combined 23.8% market share, while the remaining participants are relatively fragmented. The third to sixth largest participants (including MEDTIDE) each held approximately 1% market share in 2023.

According to prospectus data, MEDTIDE's revenue in recent years reached RMB 351 million, RMB 337 million, and RMB 442 million respectively, demonstrating strong momentum. This growth is supported by a diversified customer base and global footprint, with corporate clients spanning over 50 countries worldwide. Revenue distribution shows the United States accounting for 55%, mainland China 21.4%, Japan 7.1%, and Europe 11%. This geographically dispersed market presence effectively hedges against risks associated with dependence on a single market.